Mobile Site ›

What the FDA Relabeling of Abacavir Means for You and Your Patient



Information for Patients5

Slide 18

November 2008

For the patients, providers should inform them that they are at greater risk for serious allergic reactions when first starting treatment with abacavir or with combined therapy that contains abacavir.

Patients should be aware that HLA-B*5701 status, which is a risk-factor for these hypersensitivity reactions, should be determined prior to starting abacavir therapy.

Patients should also know that these they are at high risk for hypersensitivity reaction if their laboratory tests are positive.

Information for Patients5

 


Jump to section:


Key